(0.32%) 5 116.12 points
(0.30%) 38 356 points
(0.36%) 15 985 points
(-0.98%) $83.03
(5.36%) $2.03
(0.29%) $2 354.10
(0.34%) $27.63
(4.12%) $960.10
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
@ $13.71
発行日: 15 2月 2024 @ 01:10
リターン: 38.58%
前回のシグナル: 2月 13 - 23:37
前回のシグナル:
リターン: -1.15 %
Live Chart Being Loaded With Signals
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally...
Stats | |
---|---|
本日の出来高 | 152 973 |
平均出来高 | 131 806 |
時価総額 | 3.31B |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $0 ) 2024-05-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 31.67 |
ATR14 | $0.0380 (0.20%) |
Hutchison China MediTech 相関
10 最も負の相関 | |
---|---|
NKTX | -0.926 |
PCRX | -0.922 |
ASPS | -0.916 |
LNSR | -0.916 |
LLNW | -0.913 |
RPID | -0.908 |
CNET | -0.905 |
MEDS | -0.903 |
SMIT | -0.902 |
SFET | -0.902 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Hutchison China MediTech 財務諸表
Annual | 2023 |
収益: | $838.00M |
総利益: | $453.55M (54.12 %) |
EPS: | $0.590 |
FY | 2023 |
収益: | $838.00M |
総利益: | $453.55M (54.12 %) |
EPS: | $0.590 |
FY | 2022 |
収益: | $426.41M |
総利益: | $115.31M (27.04 %) |
EPS: | $-2.42 |
FY | 2021 |
収益: | $356.13M |
総利益: | $97.89M (27.49 %) |
EPS: | $-1.250 |
Financial Reports:
No articles found.
Hutchison China MediTech
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。